US6300503B1 - Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same - Google Patents

Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same Download PDF

Info

Publication number
US6300503B1
US6300503B1 US09/589,571 US58957100A US6300503B1 US 6300503 B1 US6300503 B1 US 6300503B1 US 58957100 A US58957100 A US 58957100A US 6300503 B1 US6300503 B1 US 6300503B1
Authority
US
United States
Prior art keywords
compound
formula
alkyl group
group
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/589,571
Inventor
Joseph C. Rongione
Robert E. Brown
Dwight E. Raff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dixie Chemical Co Inc
Original Assignee
Dixie Chemical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dixie Chemical Co Inc filed Critical Dixie Chemical Co Inc
Priority to US09/589,571 priority Critical patent/US6300503B1/en
Priority to PCT/US2000/034030 priority patent/WO2001044202A1/en
Priority to AU21048/01A priority patent/AU2104801A/en
Assigned to DIXIE CHEMICAL COMPANY reassignment DIXIE CHEMICAL COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RONGIONE, JOSEPH C., RAFF, DWIGHT E., BROWN, ROBERT G.
Application granted granted Critical
Publication of US6300503B1 publication Critical patent/US6300503B1/en
Assigned to WELLS FARGO FOOTHILL, INC., AS AGENT reassignment WELLS FARGO FOOTHILL, INC., AS AGENT SECURITY AGREEMENT Assignors: DIXIE CHEMICAL COMPANY, INC., DIXIE HOLDINGS, INC., DX OILFIELD PRODUCTS, INC., DX PHARMA, INC.
Anticipated expiration legal-status Critical
Assigned to DIXIE CHEMICAL COMPANY, INC., DIXIE HOLDINGS, INC., DX OILFIELD PRODUCTS, INC., DX PHARMA, INC. reassignment DIXIE CHEMICAL COMPANY, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: WELLS FARGO CAPITAL FINANCE, LLC
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/24Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from hydantoins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/76Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • Omapatrilat was developed at the Bristol-Myers Squibb Pharmaceutical Research Institute as the first of a new class of compounds capable of simultaneously inhibiting ACE and NEP and is currently undergoing large scale clinical trials as an anti-hypertensive. See Omapatrilat. Drugs R D 1999 Apr;1(4):350-1.
  • the invention is directed to novel compounds of the formula:
  • R 1 is —H, a C 1 -C 5 alkyl group or a benzyl group and R 2 is represented by one of the two following formulae:
  • R 3 , R 4 , R 5 , and R 6 are independently selected from the group consisting of —H or a C 1 -C 5 alkyl group and R 7 and R 8 are independently selected from the group consisting of a C 1 -C 5 alkyl group.
  • Hydantoin (III) is an intermediate in the manufacture of racemic mixture (V):
  • the S-stereoisomer, isolated from the racemic mixture, may be used, in place of compound (II), to produce omapatrilat.
  • the overall reaction sequence for production of racemic mixture (V) is:
  • Method A refers to the production of the novel hydantoin (III) of the invention directly from the monoacetal (XI).
  • Method B refers to the production of the hydantoin via the dicyano intermediate and “Method C” refers to the production of the dicyano intermediate from the monoacetal (XI).
  • the novel hydantoin is employed to produce racemic mixture (V).
  • the S-isomer, isolated from the racemic mixture, is used to produce omapatrilat.
  • Production of the racemic from the novel hydantoin of the invention is referenced as “Method D.”
  • the invention relates to novel hydantoin compounds of the formula (III):
  • the invention further relates to a process of preparing a racemic mixture of formula (IV) from the hydantoin.
  • the S-stereoisomer of the racemic mixture can be isolated and employed, as a substitute for formula (II), in the production of omapatrilat.
  • the hydantoin of the invention may be produced directly from the monoacetal of formula (XI) as well as via the dinitrile intermediate of formula (IV).
  • the overall reaction sequence to generate the racemic mixture of formula (V) may be summarized as follows:
  • R 1 is —H, a C 1 -C 5 alkyl group or a benzyl group.
  • R 1 is —H or a C 1 -C 3 alkyl group.
  • R 2 is represented by either of the two following formulae,
  • each of the R 2 groups may independently be selected from (VII) and (VIII).
  • Compound (IV) can be used as a starting material for synthesis of hydantoin (III).
  • Hydantoin (III) is used as an intermediate in the synthesis of compound (V):
  • Compound (III) may be synthesized by either Method A or Method B.
  • Method A is summarized below:
  • Any alkali cyanide, such as LiCN, as well as any organic cyanohydrin, such as a C 1 -C 6 aliphatic cyanohydrin, may be used in place of NaCN in Method A.
  • the reaction scheme for Method A presented above illustrates the use of a H 2 O/EtOH blend as reaction medium, though a pure aqueous reaction medium may be used.
  • the alcohol which may be either methanol, ethanol, isopropyl alcohol, propyl alcohol, butyl alcohol or i-butyl alcohol, increases the solubility of the monoacetal of formula (I) in water.
  • the weight ratio of water:C 1 -C 4 alcohol in the reaction medium is 1:1 or more.
  • the weight ratio of monoacetal:cyanide compound is typically between 2:1.
  • the weight ratio of cyanide:ammonium carbonate is generally 1:13; and the weight ratio of reaction medium:monoacetal is typically 28:1.
  • the reaction mixture is heated above room temperature, (20° C.). In a more preferred embodiment, the reaction mixture is heated to about 50° C. to about 57° C. The reaction mixture is allowed to react for a time sufficient to effectuate the reaction, preferably more than 2 hrs and more preferably greater than 6 hrs and even more preferably greater than 12 hours. In a preferred embodiment, the reaction product is recovered by adjusting the system pH from about 6 to about 10, preferably about 7, at which time the reaction product forms a solid white powder. The reaction is conducted at ambient pressure. Method (A) may further generate a minor amount of compound (IV) as an intermediate chemical species.
  • Suitable for use as the ammonium compound for Method C is ammonium chloride or any other inorganic ammonium compound, such as ammonium sulfate, or an organic containing ammonium compound.
  • the cyano compound used in Method A may likewise be used in Method C.
  • the weight ratio of ammonium compound:cyanide containing compound for Method C is generally about 1:1.
  • the aqueous media in Method C may be substituted with a C 1 -C 4 alkanol as discussed above for Method A.
  • the weight ratio of reaction medium to monoacetal is about 4:1 and the weight ratio of cyanide containing compound:reaction medium is about 1:12.5.
  • the reaction mixture for Method C is heated above room temperature (20° C.), preferably from 50° C. to about 52° C. at ambient temperature.
  • the reaction mixture is allowed to react for an adequate amount of time to produce the compound of formula (IV), preferably more than 10 minutes, more preferably greater than 1 hour, and most preferably 2 hours or more.
  • the pH of the reaction mixture is typically maintained between about 6 to about 10.
  • the product is recovered from the organic phase by crystallization from acetone/water, more preferably followed by washing with toluene.
  • the dicyano compound of formula (IV) may then be converted to compound (III) as shown in Method (B):
  • the use of a non-carbonate inorganic ammonium salt, such as ammonium chloride, or an organo amnmonium containing compound (versus ammonium carbonate), causes the formation of the dicyano compound (III).
  • Conversion of the dicyano compound (IV) to the hydantoin (Ill) requires the additional step of reacting the intermediate compound (IV) with carbon dioxide or a carbon dioxide generating compound such as ammonium carbonate.
  • the addition of an alkali or ammonium hydroxide is also used in order to assist in the formation of the carbon dioxide.
  • the weight ratio of carbon dioxide or carbon dioxide generating compound:hydroxide is generally between 1:1.75 and the weight ratio of carbon dioxide or carbon dioxide generating compound:reaction medium is generally 1:7.5.
  • the reaction media can be purely water or any a mixture of any of the C 1 -C 4 alcohols referenced above.
  • the reaction mixture in Method B is allowed to proceed generally at room temperature and at ambient or above atmospheric pressure (up to about 60 psig) for 10 minutes or more, more preferably for 2 hours or more and even more preferably for at least 6 hours at a pH of between from about 6 to about 10.
  • the solution is brought to a pH of 7.5.
  • the base in the reaction mixture of Method D is an alkali hydroxide, preferably either sodium hydroxide or lithium hydroxide, and the acid is preferably acetic acid, dilute hydrochloric acid or sulfuric acid, most preferably acetic acid.
  • the weight ratio of hydantoin to alkali hydroxide to reaction media is about 1:1:6.
  • the reaction mixture (D) is heated above room temperature (20° C.) and in a more preferred embodiment is heated to 100° C. or higher, and in an even more preferred embodiment is heated to 150° C.
  • the reaction mixture is allowed to react for an adequate amount of time to produce the desired racemic mixture. This adequate reaction time is preferably more than 10 minutes and more preferably greater than 1 hour and even more preferably greater than 2 hours.
  • the pH increases to about 12 or higher.
  • the reaction mixture (D) is brought to pH 7 with the acid.
  • the weight ratio of base:acid in the reaction is generally about 1:1.4.
  • Example 3 The procedure set forth in Example 3 is repeated. In place of glutaric dialdehyde monoethylene glycol acetal, about 30 g of glutaric dialdehyde monomethanol acetal is used. All other reaction conditions may remain the same.
  • Ammonium hydroxide (211 g, 2.22 equivalents; 28-30% in water) was charged and the solution was reheated to 100° C.
  • Gaseous carbon dioxide (133.2 g, slight exotherm) was fed to the reactor at such a rate as to maintain system pressure near 60-65 psig and the reaction temperature at 100° C. The system was held at 100° C. for four hours. Excess carbon dioxide was vented from the system. A portion of the water was boiled overhead to facilitate the removal of ammonia and to make room for the next step.
  • Lithium hydroxide (226.4 g, 3.33 equivalents; 10% in water) was added after the water strip. The system was brought to 150° C. for four hours.

Abstract

Omapatrilat (I) is a potent inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) both in vitro and in vivo and is currently undergoing large scale clinical trials as an anti-hypertensive. Omapatrilat may be synthesized using the S-stereoisomer of compound (V). Compound (V) may be prepared from a novel hydantoin (III). The hydantoin may be prepared from a monoacetal (XI) or via a dinitrile (V).

Description

This application claims priority from U.S. Provisional Application Ser. No. 60/172,335 filed Dec. 17, 1999 and U.S. Provisional Application Ser. No. 60/172,440 filed Dec. 17, 1999, both of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
Omapatrilat (I) is a potent inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) both in vitro and in vivo:
Figure US06300503-20011009-C00001
Omapatrilat was developed at the Bristol-Myers Squibb Pharmaceutical Research Institute as the first of a new class of compounds capable of simultaneously inhibiting ACE and NEP and is currently undergoing large scale clinical trials as an anti-hypertensive. See Omapatrilat. Drugs R D 1999 Apr;1(4):350-1.
Currently, omapatrilat is synthesized using (S)-hydroxy amino acid (II) as one of the key starting materials:
Figure US06300503-20011009-C00002
The hydroxyl group of compound (II) must be converted to an aldehyde as a prerequisite step in the syntheis of compound (I), omapatrilat. This oxidation to an aldehyde currently requires several steps and/or noxious reagents. See Robl, J. A., et al. J. Med. Chem. 1997, 40, 1570-1577; Robl, J. A. et al. J. Med. Chem. 1996, 39 494-502.
It is therefore desirable to find alternatives to compound (II) that reduce the number of requisite synthetic steps and eliminate the use of noxious reagents.
SUMMARY OF THE INVENTION
The invention is directed to novel compounds of the formula:
Figure US06300503-20011009-C00003
wherein R1 is —H, a C1-C5 alkyl group or a benzyl group and R2 is represented by one of the two following formulae:
Figure US06300503-20011009-C00004
wherein R3, R4, R5, and R6 are independently selected from the group consisting of —H or a C1-C5 alkyl group and R7 and R8 are independently selected from the group consisting of a C1-C5 alkyl group.
The invention further relates to a method of producing and using the hydantoins of formula (III). Such compounds may be produced directly from a monoacetal (XI)
Figure US06300503-20011009-C00005
or via a dinitrile intermediate of formula (IV):
Figure US06300503-20011009-C00006
Hydantoin (III) is an intermediate in the manufacture of racemic mixture (V):
Figure US06300503-20011009-C00007
The S-stereoisomer, isolated from the racemic mixture, may be used, in place of compound (II), to produce omapatrilat. The overall reaction sequence for production of racemic mixture (V) is:
Figure US06300503-20011009-C00008
As used herein, “Method A” refers to the production of the novel hydantoin (III) of the invention directly from the monoacetal (XI). “Method B” refers to the production of the hydantoin via the dicyano intermediate and “Method C” refers to the production of the dicyano intermediate from the monoacetal (XI).
In another aspect of the invention, the novel hydantoin is employed to produce racemic mixture (V). The S-isomer, isolated from the racemic mixture, is used to produce omapatrilat. Production of the racemic from the novel hydantoin of the invention is referenced as “Method D.”
The use of compound (V) with its protected aldehyde avoids the need to oxidize the alcohol on compound (II) and thus reduces the number of steps necessary for the synthesis of omapatrilat and further avoid the use of noxious chemicals. See Robl, J. A., et al. J. Med. Chem. 1997, 40, 1570-1577; Robl, J. A. et al. J. Med. Chem. 1996, 39, 494-502.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The invention relates to novel hydantoin compounds of the formula (III):
Figure US06300503-20011009-C00009
and to processes of preparing the same. The invention further relates to a process of preparing a racemic mixture of formula (IV) from the hydantoin. The S-stereoisomer of the racemic mixture can be isolated and employed, as a substitute for formula (II), in the production of omapatrilat.
The hydantoin of the invention may be produced directly from the monoacetal of formula (XI) as well as via the dinitrile intermediate of formula (IV). The overall reaction sequence to generate the racemic mixture of formula (V) may be summarized as follows:
Figure US06300503-20011009-C00010
In the reaction sequence, R1 is —H, a C1-C5 alkyl group or a benzyl group. In a preferred embodiment, R1 is —H or a C1-C3 alkyl group. In the sequence above, R2is represented by either of the two following formulae,
Figure US06300503-20011009-C00011
wherein R3, R4, R5, and R6 are independently selected from the group consisting of —H or a C1-C5 alkyl group. (In a preferred embodiment R3, R4, R5, and R6 are independently selected from a group consisting of —H or a C1-C3 alkyl group. In a more preferred embodiment R3, R4, R5, and R6 are independently selected from the group consisting of a C1-C3 alkyl group; or R3, R4, R5, and R6 are all —H);
R7 and R8 are independently selected from a group consisting of a C1-C5 alkyl group. In a preferred embodiment R7 and R8 are independently selected from a group consisting of a C1-C3 alkyl group.
Where the dinitrile (IV) is employed, each of the R2 groups may independently be selected from (VII) and (VIII). Compound (IV) can be used as a starting material for synthesis of hydantoin (III). Hydantoin (III) is used as an intermediate in the synthesis of compound (V):
Figure US06300503-20011009-C00012
The S stereoisomer of compound (V) may be obtained by subjecting the racemic mixture of formula (V) to amidation in water. A molar excess (generally 10 to 20 percent excess) of acetic anhydride is typically used to ensure complete acylation of all of the nitrogen groups on the compound of formula (V). The reaction is conducted at approximately 35° C. The amide linkage on the desired S-isomer may then be cleaved by enzymatic activity, thereby leaving the undesired R isomer in solution. The free amino acid is then collected and purified. The S stereoisomer of compound (V) may be purified in the same manner as the (S)-hydroxy amino acid compound (II) with a theoretical yield of 50%. (See Robl, J. A., et al. J. Med. Chem. 1997, 40, 1570-1577). The purified isomer may then be used to substitute for compound (II) as a synthetic starting material for generating omapatrilat.
An advantage in using compound (V) with its protected aldehyde is that it avoids the need to oxidize the alcohol on compound (II) and thus reduces the number of steps necessary for the synthesis of omapatrilat. It further avoids the use of noxious chemicals often employed in the oxidation of compound (II). See Robl, J. A., et al. J. Med. Chem. 1997, 40, 1570-1577; Robl, J. A., et al. J. Med. Chem. 1996, 39, 494-502.
An additional advantage in using compound (III) in the synthesis is the high efficiency evidenced when converting compound (III) to the S stereoisomer of compound (V). Hydantoins, such as compound (III), can be enzymatically racemized so that resolved R stereoisomer can be converted to and purified as the S stereoisomer, thereby increasing the possible yields of the desired S stereoisomer.
Compound (III) may be synthesized by either Method A or Method B. Method A is summarized below:
Figure US06300503-20011009-C00013
Any alkali cyanide, such as LiCN, as well as any organic cyanohydrin, such as a C1-C6 aliphatic cyanohydrin, may be used in place of NaCN in Method A. The reaction scheme for Method A presented above illustrates the use of a H2O/EtOH blend as reaction medium, though a pure aqueous reaction medium may be used. The alcohol, which may be either methanol, ethanol, isopropyl alcohol, propyl alcohol, butyl alcohol or i-butyl alcohol, increases the solubility of the monoacetal of formula (I) in water. Typically, the weight ratio of water:C1-C4 alcohol in the reaction medium is 1:1 or more. The weight ratio of monoacetal:cyanide compound is typically between 2:1. The weight ratio of cyanide:ammonium carbonate is generally 1:13; and the weight ratio of reaction medium:monoacetal is typically 28:1.
In a preferred embodiment, the reaction mixture is heated above room temperature, (20° C.). In a more preferred embodiment, the reaction mixture is heated to about 50° C. to about 57° C. The reaction mixture is allowed to react for a time sufficient to effectuate the reaction, preferably more than 2 hrs and more preferably greater than 6 hrs and even more preferably greater than 12 hours. In a preferred embodiment, the reaction product is recovered by adjusting the system pH from about 6 to about 10, preferably about 7, at which time the reaction product forms a solid white powder. The reaction is conducted at ambient pressure. Method (A) may further generate a minor amount of compound (IV) as an intermediate chemical species.
The dicyano compound of formula (IV) is principally produced when the source of ammonium ion, i.e., ammonium carbonate in Method A, is replaced with another inorganic or an organic ammonium salt. The synthesis denoted as Method C may be schematically represented as:
Figure US06300503-20011009-C00014
Suitable for use as the ammonium compound for Method C is ammonium chloride or any other inorganic ammonium compound, such as ammonium sulfate, or an organic containing ammonium compound. The cyano compound used in Method A may likewise be used in Method C. The weight ratio of ammonium compound:cyanide containing compound for Method C is generally about 1:1. In addition, the aqueous media in Method C may be substituted with a C1-C4 alkanol as discussed above for Method A. The weight ratio of reaction medium to monoacetal is about 4:1 and the weight ratio of cyanide containing compound:reaction medium is about 1:12.5.
In a preferred embodiment the reaction mixture for Method C is heated above room temperature (20° C.), preferably from 50° C. to about 52° C. at ambient temperature. The reaction mixture is allowed to react for an adequate amount of time to produce the compound of formula (IV), preferably more than 10 minutes, more preferably greater than 1 hour, and most preferably 2 hours or more. The pH of the reaction mixture is typically maintained between about 6 to about 10. In a preferred embodiment, the product is recovered from the organic phase by crystallization from acetone/water, more preferably followed by washing with toluene.
The dicyano compound of formula (IV) may then be converted to compound (III) as shown in Method (B):
Figure US06300503-20011009-C00015
Thus, the use of a non-carbonate inorganic ammonium salt, such as ammonium chloride, or an organo amnmonium containing compound (versus ammonium carbonate), causes the formation of the dicyano compound (III). Conversion of the dicyano compound (IV) to the hydantoin (Ill) requires the additional step of reacting the intermediate compound (IV) with carbon dioxide or a carbon dioxide generating compound such as ammonium carbonate. In a preferred embodiment, the addition of an alkali or ammonium hydroxide is also used in order to assist in the formation of the carbon dioxide. The weight ratio of carbon dioxide or carbon dioxide generating compound:hydroxide is generally between 1:1.75 and the weight ratio of carbon dioxide or carbon dioxide generating compound:reaction medium is generally 1:7.5.
In place of the H2O/EtOH mixture, the reaction media can be purely water or any a mixture of any of the C1-C4 alcohols referenced above. The reaction mixture in Method B is allowed to proceed generally at room temperature and at ambient or above atmospheric pressure (up to about 60 psig) for 10 minutes or more, more preferably for 2 hours or more and even more preferably for at least 6 hours at a pH of between from about 6 to about 10. In a preferred embodiment, the solution is brought to a pH of 7.5.
Compound (V) is produced from the hydantoin as summarized in Method D:
Figure US06300503-20011009-C00016
The base in the reaction mixture of Method D is an alkali hydroxide, preferably either sodium hydroxide or lithium hydroxide, and the acid is preferably acetic acid, dilute hydrochloric acid or sulfuric acid, most preferably acetic acid. The weight ratio of hydantoin to alkali hydroxide to reaction media is about 1:1:6. In a preferred embodiment the reaction mixture (D) is heated above room temperature (20° C.) and in a more preferred embodiment is heated to 100° C. or higher, and in an even more preferred embodiment is heated to 150° C. The reaction mixture is allowed to react for an adequate amount of time to produce the desired racemic mixture. This adequate reaction time is preferably more than 10 minutes and more preferably greater than 1 hour and even more preferably greater than 2 hours. During the reaction, the pH increases to about 12 or higher. The reaction mixture (D) is brought to pH 7 with the acid. The weight ratio of base:acid in the reaction is generally about 1:1.4.
The following examples will illustrate the practice of the present invention in its preferred embodiments. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification and practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow.
EXAMPLE 1 Synthesis of Representative Species of Compound (IV) wherein R2 is Formula (VIII)
Water (30 g), glutaric dialdehyde monoethylene glycol acetal (monoacetal, 15.1 g) and amnmonium chloride (5.58 g) were added together in a 100 mL round bottom flask (mixing by magnetic stirrer). Next sodium cyanide (4.80 g in 20.9 g water) was added. A 16° C. temperature rise was noted. The reaction mixture was heated to 50-52° C. and held at this temperature for 2 hours. The lower organic phase was separated from the upper aqueous phase. The aqueous phase was twice washed with methylene chloride. After solvent removal, the oil was crystallized from acetone/water. After washing with toluene, the white solid was dried.
1H NMR data (300 MHz, (CD3)2SO): δ1.5-1.9 (m, 12H), 3.76 (m, 1H), 3.8-4.0 (m, 10H 4.8 (m, 2H). 13C NMR data (75 MHz, (CD3)2SO): δ19.6, 32.5, 33.2, 48.1 64.2, 103.4, 120.0. Mass Spectroscopy data (+CI) m/z (relative intensity): 297 (M+ −HCN, 21), 270 (M+ −2 HCN, 27), 235 (M+ —HCN,CH2CH2O, H2O, 25), 208 (M+ −2 HCN, CH2CH2O, H2O, 100). Anal. Calcd for C16H25N3O4: C, 59.43; H, 7.79; N, 12.99. Found: C, 59.48; H, 7.92; N, 12.87.
End product C16H25N3O4, Compound (IX), is represented by the formula:
Figure US06300503-20011009-C00017
EXAMPLE 2 Synthesis of Representative Species of Compound (IV) wherein R2 is Formula (VII)
The procedure set forth in Example 1 is repeated. In place of glutaric dialdehyde monoethylene glycol acetal, about 15 g of glutaric dialdehyde dimethanol acetal is used. All other reaction conditions may remain the same.
EXAMPLE 3 Synthesis Representative Species of Compound (III) wherein R2 is Formula (VIII)
Water (190 g) was added to a 2 liter round bottom flask (mechanically stirred). Next, ammonium carbonate (174.9 g) was added to the water. More water (195 g) and ethanol (385 g) were added to the flask, followed by sodium cyanide (13.3 g). Glutaric dialdehyde monoethylene glycol acetal (monoacetal, 30.0 g) was added in one portion. A 7° C. temperature rise was noted. The reaction mixture was heated to 50-57° C. and held at this temperature for 12.3 hours. The reaction volume was reduced (490.8 g taken as overhead). System pH was brought to 7 with 25% H2SO4 at which time a solid white powder formed in the flask. The solid was recrystallized from water and dried.
End product, compound (X), is represented by the formula:
Figure US06300503-20011009-C00018
EXAMPLE 4 Synthesis Representative Species of Compound (III) wherein R2 is formula (VII)
The procedure set forth in Example 3 is repeated. In place of glutaric dialdehyde monoethylene glycol acetal, about 30 g of glutaric dialdehyde monomethanol acetal is used. All other reaction conditions may remain the same.
EXAMPLE 5 Second Synthesis Scheme for Representative Species of Compound (III)
Water (30 g), glutaric dialdehyde monoethylene glycol acetal (monoacetal, 15.1 g) and ammonium chloride (5.58 g) were added together in a 100 mL round bottom flask (on a magnetic stirrer). Next, sodium cyanide (4.80 g in 20.9 g water) was added over 10 minutes. The reaction was heated to 50-52° C. and held at this temperature for 2 hours. Both phases were transferred to a pressure vessel. The system was heated to 100° C. and carbon dioxide was fed to the reactor. Maximum system pressure was 60 psig. After 6 hours, the solution was cooled and brought to pH 7.5 with acetic acid. The hydantoin was recovered as a white solid.
EXAMPLE 6 Synthesis of Racemic Mixture of Formula (V)
Ammonium chloride (90.8 g, 1.70 moles) in water (1000 g) was cooled to 0-5 C. Next, monoacetal (246 g. 1.17% dialdehyde, 3.56% bisacetal, 1.63 moles) was added to the ammonium chloride solution. While maintaining the system temperature between 0-10 C. sodium cyanide (79.3 g, 1.62 moles; in 313.4 g water and 3.9 g 50% NaOH aq. Soln., CAUTION: toxic, exotherm) was added below the surface of the monoacetal solution. Upon completion of the addition the solution was heated to 50° C. for six hours. The solution was cooled to 30° C. Ammonium hydroxide (211 g, 2.22 equivalents; 28-30% in water) was charged and the solution was reheated to 100° C. Gaseous carbon dioxide (133.2 g, slight exotherm) was fed to the reactor at such a rate as to maintain system pressure near 60-65 psig and the reaction temperature at 100° C. The system was held at 100° C. for four hours. Excess carbon dioxide was vented from the system. A portion of the water was boiled overhead to facilitate the removal of ammonia and to make room for the next step. Lithium hydroxide (226.4 g, 3.33 equivalents; 10% in water) was added after the water strip. The system was brought to 150° C. for four hours. The reaction system was then cooled, filtered (235.2 g wet cake) and neutralized with acetic acid (310 g) to a pH of 7.2-7.4. After a water strip (1878.3 g overhead) methanol (2400 g) was added to precipitate the racemic amino acid. The white solid was washed with cold methanol after recovery. A racemic mixture of formula (V) wherein R2 is (VIII) was obtained.

Claims (38)

What is claimed is:
1. A compound of the formula:
Figure US06300503-20011009-C00019
wherein R1 is —H, a C1-C5 alkyl group or benzyl, and R2 is represented by the formula:
Figure US06300503-20011009-C00020
wherein R3, R4, R5, and R6 are independently selected from the group consisting of —H or a C1-C5 alkyl group and R7 and R8 are independently selected from the group consisting of a C1-C5 alkyl group.
2. The compound of claim 1, wherein R2 is of the formula:
Figure US06300503-20011009-C00021
3. The compound of claim 2, wherein R3, R4, R5, and R6 are independently selected from the group consisting of —H or a C1-C3 alkyl group.
4. The compound of claim 3, wherein R3, R4, R5, and R6 are all hydrogen.
5. The compound of claim 2, wherein R1 is hydrogen.
6. The compound of claim 1, wherein R1 is hydrogen.
7. The compound of claim 1, wherein R1 is a C1-C5 alkyl group.
8. The compound of claim 5, wherein R3, R4, R5, and R6 are all hydrogen.
9. The compound of claim 1, wherein R2 is
Figure US06300503-20011009-C00022
10. The compound of claim 9, wherein R7 and R8 are independently selected from the group consisting of a C1-C3 alkyl group.
11. The compound of claim 9, wherein R1 is —H.
12. The compound of claim 9, wherein R1 is a C1-C5 alkyl group.
13. The compound of claim 9, wherein R1 is benzyl.
14. A process of preparing a compound of the formula:
Figure US06300503-20011009-C00023
wherein R1 is —H, a C1-C5 alkyl group, or benzyl and R2 is represented by the formula:
Figure US06300503-20011009-C00024
wherein R3, R4, R5, and R6 are independently selected from the group consisting of —H or a C1-C5 alkyl group and R7 and R8 are independently selected from the group consisting of a C1-C5 alkyl group, said process comprising mixing monoacetal having the formula:
Figure US06300503-20011009-C00025
with ammonium carbonate and either an alkali cyanide or a cyanohydrin for a time and at a temperature sufficient to render a compound of formula (III).
15. The process of claim 14, wherein the mixture is maintained at a temperature greater than 20° C.
16. The process of claim 14, wherein the alkali cyanide is sodium or lithium cyanide.
17. The process of claim 15, wherein the mixture is maintained at a temperature of between about 50° C. to about 57° C.
18. The process of claim 14, wherein the monoacetal and ammonium carbonate are admixed for at least 2 hours.
19. The process of claim 14, wherein R2 is
Figure US06300503-20011009-C00026
20. The process of claim 14, wherein R2 is:
Figure US06300503-20011009-C00027
21. A compound of the formula:
Figure US06300503-20011009-C00028
wherein R1 is —H, a C1-C5 alkyl group, or benzyl and R2 is represented by the formula:
Figure US06300503-20011009-C00029
and further wherein R3, R4, R5, and R6 are independently selected from the group consisting of —H or a C1-C5 alkyl group and R7 and R8 are independently selected from the group consisting of a C1-C5 alkyl group, produced by the process of claim 14.
22. A process of preparing a hydantoin of the formula:
Figure US06300503-20011009-C00030
wherein R1 is —H, a C1-C5 alkyl group, or benzyl and R2 is represented by the formula:
Figure US06300503-20011009-C00031
wherein R3, R4, R5, and R6 are independently selected from the group consisting of —H or a C1-C5 alkyl group and R7 and R8 are independently selected from the group consisting of a C1-C5 alkyl group, said process comprising mixing a dinitrile having the formula:
Figure US06300503-20011009-C00032
with carbon dioxide or a carbon dioxide generating compound in an aqueous medium for a time and at a temperature sufficient to generate the compound of formula (III).
23. The process of claim 22, wherein the carbon dioxide generating compound is ammonium carbonate.
24. The process of claim 22, wherein the reaction proceeds at a pressure from about ambient to about 60 psig.
25. The process of claim 22, wherein the dinitrile and carbon dioxide or carbon dioxide generating compound are admixed for at least 10 minutes.
26. The process of claim 25, wherein the dinitrile and carbon dioxide or carbon dioxide generating compound are admixed for at least 2 hours.
27. The process of claim 26, wherein the dinitrile and carbon dioxide or carbon dioxide generating compound are admixed for at least 6 hours.
28. A hydantoin of the formula (III):
Figure US06300503-20011009-C00033
wherein R1 is —H, a C1-C5 alkyl group, or benzyl and R2 is represented by the formula:
Figure US06300503-20011009-C00034
wherein R3, R4, R5, and R6 are independently selected from the group consisting of —H or a C1-C5 alkyl group and R7 and R8 are independently selected from the group consisting of a C1-C5 alkyl group produced by the process of claim 22.
29. A process of preparing a compound of the formula:
Figure US06300503-20011009-C00035
wherein R2 is either
Figure US06300503-20011009-C00036
wherein R3, R4, R5, and R6 are independently selected from the group consisting of —H or a C1-C5 alkyl group and R7 and R8 are independently selected from the group consisting of a C1-C5 alkyl group, said process comprising mixing a hydantoin having the formula:
Figure US06300503-20011009-C00037
wherein R1 is —H, a C1-C5 alkyl group or benzyl under alkaline conditions for a time and at a temperature sufficient to generate the compound of formula (V).
30. The process of claim 29, wherein the mixture is heated at a temperature between from about 100° to about 150° C.
31. The process of claim 29, wherein the alkaline is the combination of an alkali hydroxide and an acid.
32. The process of claim 31, wherein the acid is acetic acid.
33. The process of claim 29, wherein the hydantoin is prepared by mixing monoacetal having the formula:
Figure US06300503-20011009-C00038
with amnmonium carbonate and an alkali cyanide or a cyanohydrin for a time and at a temperature sufficient to render the hydantoin.
34. The process of claim 33, wherein the hydantoin and acetal are mixed at a temperature of from about 50° C. to about 57° C.
35. The process of claim 33, wherein R2 is
Figure US06300503-20011009-C00039
36. The process of claim 29, wherein the hydantoin is prepared by mixing a dinitrile having the formula:
Figure US06300503-20011009-C00040
with carbon dioxide or a carbon dioxide generating compound in an aqueous medium for a time and at a temperature sufficient to generate the hydantoin.
37. The process of claim 36, wherein the mixture is heated at about at a temperature from about 100° to about 150° C. at a pressure from about ambient to about 60 psig.
38. The process of claim 36, wherein the dinitrile is prepared by mixing monacetal having the formula:
Figure US06300503-20011009-C00041
with a non-carbonate ammonium salt and an alkali cyanide for a time and at a temperature sufficient to generate the dinitrile.
US09/589,571 1999-12-17 2000-06-07 Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same Expired - Fee Related US6300503B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/589,571 US6300503B1 (en) 1999-12-17 2000-06-07 Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same
PCT/US2000/034030 WO2001044202A1 (en) 1999-12-17 2000-12-15 Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same
AU21048/01A AU2104801A (en) 1999-12-17 2000-12-15 Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17244099P 1999-12-17 1999-12-17
US17233599P 1999-12-17 1999-12-17
US09/589,571 US6300503B1 (en) 1999-12-17 2000-06-07 Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same

Publications (1)

Publication Number Publication Date
US6300503B1 true US6300503B1 (en) 2001-10-09

Family

ID=27390124

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/589,571 Expired - Fee Related US6300503B1 (en) 1999-12-17 2000-06-07 Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same

Country Status (3)

Country Link
US (1) US6300503B1 (en)
AU (1) AU2104801A (en)
WO (1) WO2001044202A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620600B2 (en) 2000-09-15 2003-09-16 Bristol-Myers Squibb Co. Enzymatic resolution of aryl and thio-substituted acids

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424783A (en) 1966-05-06 1969-01-28 Grace W R & Co Aminonitrile synthesis
US3862203A (en) 1967-12-18 1975-01-21 Stauffer Chemical Co Process of manufacturing nitrilotriacetonitrile
US4039527A (en) 1974-10-04 1977-08-02 Wako Pure Chemical Industries, Ltd. Unsymmetrical azonitriles
US4315022A (en) * 1979-05-23 1982-02-09 Beecham Group Limited Terminal amino prostaglandin analogues
US4543215A (en) 1982-11-15 1985-09-24 Basf Aktiengesellschaft α-iminodiacetonitriles and their preparation
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5663363A (en) * 1996-11-21 1997-09-02 American Home Products Corporation 2-thioxo-imidazolidin-4-one derivatives
US5691335A (en) * 1994-07-29 1997-11-25 Suntory Limited Imidazolidine derivative and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3638425B2 (en) * 1998-01-29 2005-04-13 第一化学薬品株式会社 Process for producing optically active α-aminoadipic acid-γ-semialdehyde ethylene acetal

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424783A (en) 1966-05-06 1969-01-28 Grace W R & Co Aminonitrile synthesis
US3862203A (en) 1967-12-18 1975-01-21 Stauffer Chemical Co Process of manufacturing nitrilotriacetonitrile
US4039527A (en) 1974-10-04 1977-08-02 Wako Pure Chemical Industries, Ltd. Unsymmetrical azonitriles
US4315022A (en) * 1979-05-23 1982-02-09 Beecham Group Limited Terminal amino prostaglandin analogues
US4543215A (en) 1982-11-15 1985-09-24 Basf Aktiengesellschaft α-iminodiacetonitriles and their preparation
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5691335A (en) * 1994-07-29 1997-11-25 Suntory Limited Imidazolidine derivative and use thereof
US5663363A (en) * 1996-11-21 1997-09-02 American Home Products Corporation 2-thioxo-imidazolidin-4-one derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Callahan, J. F., et al., "Synthesis of 6, 6-Pentamethylene-2-aminosuberic Acid. A Key Intermediate in the Synthesis of Dicarba Analogues of Vasopressin Antagonists", Journal of Organic Chemistry, vol. 53, No. 7,1988, pp. 12527-30, XP-000984682
Gaudry, R., "The Synthesis of D, L-alpha-Amino-epsi-Hydroxycaproic Acid and a New Synthesis of D, L-Lysine" Canadian J. Res. Sect. B, vol. 26, 1948, pp. 387-392, XP000984801.
Gaudry, R., "The Synthesis of D, L-α-Amino-ε-Hydroxycaproic Acid and a New Synthesis of D, L-Lysine" Canadian J. Res. Sect. B, vol. 26, 1948, pp. 387-392, XP000984801.
Robl Et Al., "Dual Metalloprotease Inhibitors. 6. Incorporation of Bicyclic and Substituted Monocyclic Azepinones as Dipeptide Surrogates in Angiotensin-Coverting Enzyme/Neutral Endopeptidase Inhibitors," J. Med. Chem., 1996, 39, 494-502, Princeton, New Jersey.
Robl et al., "Dual Metalloprotease Inhibitors: Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase," J. Med. Chem., 1997, 40, 1570-1577, Princeton, New Jersey.
Rousset, A., et al. "Systèmes de strecker et Apparentés XI", vol. 36, 1980, pp. 2649-2661, XP002164112 p. 2649-2661.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620600B2 (en) 2000-09-15 2003-09-16 Bristol-Myers Squibb Co. Enzymatic resolution of aryl and thio-substituted acids
US20040072310A1 (en) * 2000-09-15 2004-04-15 Jingyang Zhu Enzymatic resolution of aryl and thio-substituted acids
US20040077061A1 (en) * 2000-09-15 2004-04-22 Jingyang Zhu Enzymatic resolution of aryl and thio-substituted acids
US7026143B2 (en) 2000-09-15 2006-04-11 Bristol-Myers Squibb Company Enzymatic resolution of aryl and thio-substituted acids
US7141694B2 (en) 2000-09-15 2006-11-28 Bristol-Myers Squibb Company Enzymatic resolution of aryl and thio-substituted acids

Also Published As

Publication number Publication date
AU2104801A (en) 2001-06-25
WO2001044202A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
US20090137797A1 (en) Organic Compounds
KR100421073B1 (en) Preparation of substituted perhydroisoindoles
US4297282A (en) Resolution of mercaptopropionic acids
KR20060052532A (en) Hydroxynaphthoic acid hydrazide compound and method for preparing the same
Ohashi et al. A new method for 5-(4-hydroxyphenyl) hydantoin synthesis
KR101050018B1 (en) Improved method for producing nitroguanidine derivative
EP0499376A1 (en) Precipitation-induced asymmetric transformation of chiral alpha-amino acids and salts thereof
US6300503B1 (en) Hydantoin intermediates for the synthesis of omapatrilat and methods for producing and using the same
US6284901B1 (en) Dinitrile intermediates for the synthesis of omapatrilat and methods for producing same
US20100041876A1 (en) Process for preparing aromatic diazonium salts
JPS6013775A (en) Production of optically active 3-(p-alkoxyphenyl)-glycidic acid alkali metal salt
KR102622104B1 (en) Preparation method of benzoic acid amide compounds
JP4308327B2 (en) Method for producing 1,4,7,10-tetraazacyclododecane
EP1243576B1 (en) Processes for producing (aminomethyl)trifluoromethylcarbinol derivatives
JP3831954B2 (en) Process for producing 4-hydroxy-2-pyrrolidone
JP4212473B2 (en) Process for preparing (R)-or (S) -aminocarnitine inner salt, salt and derivative thereof
JP4532801B2 (en) Method for preparing (-)-(1S, 4R) N protected 4-amino-2-cyclopentene-1-carboxylic acid ester
CZ150194A3 (en) Process for preparing nitriles of aminopropionic acid
JP3357570B2 (en) Method for producing 3-substituted-1-propanol
US5929242A (en) Manufacture of levobupivacaine and analogues thereof from L-lysine
EP0483674B1 (en) A process for producing an aliphatic amide and salts thereof
KR100850558B1 (en) Process for preparing useful in synthesis of atorvastatin
JPS63165354A (en) Production of asymmetric cyanhydrin
US5840972A (en) Process for preparing NG -monoalkyl-L-arginine and related compounds
JPS62178556A (en) Manufacture of alpha-amino-alpha-hydrogen-carboxylic acid amide

Legal Events

Date Code Title Description
AS Assignment

Owner name: DIXIE CHEMICAL COMPANY, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RONGIONE, JOSEPH C.;BROWN, ROBERT G.;RAFF, DWIGHT E.;REEL/FRAME:011479/0088;SIGNING DATES FROM 20000122 TO 20001114

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: WELLS FARGO FOOTHILL, INC., AS AGENT, MASSACHUSETT

Free format text: SECURITY AGREEMENT;ASSIGNORS:DIXIE HOLDINGS, INC.;DIXIE CHEMICAL COMPANY, INC.;DX OILFIELD PRODUCTS, INC.;AND OTHERS;REEL/FRAME:018268/0297

Effective date: 20060731

FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

REFU Refund

Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: R1552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20131009

AS Assignment

Owner name: DIXIE HOLDINGS, INC., TEXAS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WELLS FARGO CAPITAL FINANCE, LLC;REEL/FRAME:056839/0542

Effective date: 20210628

Owner name: DIXIE CHEMICAL COMPANY, INC., TEXAS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WELLS FARGO CAPITAL FINANCE, LLC;REEL/FRAME:056839/0542

Effective date: 20210628

Owner name: DX OILFIELD PRODUCTS, INC., TEXAS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WELLS FARGO CAPITAL FINANCE, LLC;REEL/FRAME:056839/0542

Effective date: 20210628

Owner name: DX PHARMA, INC., TEXAS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WELLS FARGO CAPITAL FINANCE, LLC;REEL/FRAME:056839/0542

Effective date: 20210628